The Competition Commission of India held that higher hospital charges alone do not establish abuse of dominance without proof that prices were excessive and unfair. The case against the hospital was closed for lack of sufficient evidence.
The CCI found that the investigation failed to compare hospital charges with similarly placed hospitals and relied on inadequate benchmarks such as standalone labs and hotels. The Commission therefore held that unfair pricing was not conclusively proved.
The CCI held that higher prices charged by a private super-specialty hospital for tests, medicines, and consumables did not automatically amount to abuse of dominance. The Commission found no sufficient evidence proving that the pricing was both excessive and unfair.
The Commission observed that patients commonly seek treatment across Delhi-NCR and therefore defined the relevant geographic market broadly rather than limiting it to Delhi alone.
Competition Commission of India held that hospital rooms provide medical infrastructure, emergency support, and trained healthcare staff, making them fundamentally different from hotel accommodations. It therefore rejected findings based on comparisons between hospital room rents and hotel tariffs.
Commission found that comparisons between hospital diagnostic charges and standalone labs were inadequate because hospitals operate continuously with different infrastructure requirements.
The Competition Commission of India held that allegations of excessive pricing for medicines, tests, and consumables were not conclusively established. The case was closed after the Commission found insufficient evidence of abuse of dominant position.
The CCI observed that there was no evidence that medicines or consumables were sold above manufacturer-fixed MRPs. The Commission held that profit margins alone were insufficient to establish abuse of dominance.
The Competition Commission of India held that allegations of excessive pricing for room rent, medical tests, medicines, and consumables were not supported by sufficient evidence.
The CCI held that allegations of excessive pricing for medicines, consumables, room rent, and diagnostic services were not substantiated. The Commission found that patients could assess treatment costs beforehand and no separate aftermarket was established.
